Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention

  • Obel, J (Department of Obstetrics and Gynaecology, Hvidovre Hospital, University of Copenhagen) ;
  • McKenzie, J (Public Health Division, Secretariat of the Pacific Community) ;
  • Buenconsejo-Lum, LE (John A. Burns School of Medicine, University of Hawaii) ;
  • Durand, AM (Pacific Islands Health Officers Association) ;
  • Ekeroma, A (Pacific Society for Reproductive Health Charitable Trust) ;
  • Souares, Y (Public Health Division, Secretariat of the Pacific Community) ;
  • Hoy, D (Public Health Division, Secretariat of the Pacific Community) ;
  • Baravilala, W (Asia Pacific Regional Office, United Nations Population Fund) ;
  • Garland, SM (Royal Women's Hospital, Murdoch Childrens Research Institute, Parkville, Department of Obstetrics and Gynaecology, University of Melbourne) ;
  • Kjaer, SK (Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, and Gynecologic Clinic, Rigshospitalet, University of Copenhagen) ;
  • Roth, A (Public Health Division, Secretariat of the Pacific Community)
  • Published : 2015.04.29


Objective : To provide background information for strengthening cervical cancer prevention in the Pacific by mapping current human papillomavirus (HPV) vaccination and cervical cancer screening practices, as well as intent and barriers to the introduction and maintenance of national HPV vaccination programmes in the region. Materials and Methods: A cross-sectional questionnaire-based survey among ministry of health officials from 21 Pacific Island countries and territories (n=21). Results: Cervical cancer prevention was rated as highly important, but implementation of prevention programs were insufficient, with only two of 21 countries and territories having achieved coverage of cervical cancer screening above 40%. Ten of 21 countries and territories had included HPV vaccination in their immunization schedule, but only two countries reported coverage of HPV vaccination above 60% among the targeted population. Key barriers to the introduction and continuation of HPV vaccination were reported to be: (i) Lack of sustainable financing for HPV vaccine programs; (ii) Lack of visible government endorsement; (iii) Critical public perception of the value and safety of the HPV vaccine; and (iv) Lack of clear guidelines and policies for HPV vaccination. Conclusion: Current practices to prevent cervical cancer in the Pacific Region do not match the high burden of disease from cervical cancer. A regional approach, including reducing vaccine prices by bulk purchase of vaccine, technical support for implementation of prevention programs, operational research and advocacy could strengthen political momentum for cervical cancer prevention and avoid risking the lives of many women in the Pacific.


Pacific;cervical cancer;human papillomavirus;vaccination;screening practice


  1. Akinyemiju TF (2012). Socio-economic and health access determinants of breast and cervical cancer screening in low-income countries: analysis of the World Health Survey. PLoS One, 7, 48834.
  2. Ali H, Donovan B, Wand H, et al (2013). Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, 346, 2032.
  3. Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT (2008). Introduction of human papillomavirus vaccines into developing countries-international strategies for funding and procurement. Vaccine, 26, 87-92.
  4. Aruhuri B, Tarivonda L, Tennet V, et al (2012). Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu. Cancer Prev Res, 5, 746-53.
  5. Balajadia RG, Wenzel L, Huh J, Sweningson J, Hubbell FA (2008). Cancer-related knowledge, attitudes, and behaviors among Chamorros on Guam. Cancer Detect Prev, 32, 4-15.
  6. Baandup L, Blomberg M, Dehlendorff C, et al (2013). Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis, 40, 130-5.
  7. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK (2014). Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst, 106, 460.
  8. Broutet N, Lehnertz N, Mehl G, et al (2013). Effective health interventions for adolescents that could be integrated with human papillomavirus vaccination programs. J Adolesc Health, 53, 6-13.
  9. Buenconsejo-Lum LE, Navasca D, Jeong Y, et al (2014). Cancer in the US Affiliated Pacific Islands 2007-2011. Pacific Regional Central Cancer Registry [Online]. Available: [Accessed 9th of January 2015].
  10. Clifford GM, Smith JS, Aguado T, Franceschi S (2003). Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer, 89, 101-5.
  11. Colombara DV, Wang SM (2013). The impact of HPV vaccination delays in China: lessons from HBV control programs. Vaccine, 31, 4057-9.
  12. Denny L, Anorlu R (2012). Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev, 21, 1434-8.
  13. Dobson SR, McNeil S, Dionne M, et al (2013). Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA, 309, 1793-802.
  14. Ferlay J, Shin HR, Bray F et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  15. Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, 359-86.
  16. Fesenfeld M, Hutubessy R, Jit M (2013). Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine, 31, 3786-804.
  17. Foliaki S, Best D, Akau'ola S, et al (2011). Cancer incidence in four pacific countries: Tonga, Fiji Islands, cook Islands and Niue. Pac Health Dialog, 17, 21-32.
  18. Garland SM, Hernandez-Avila M, Wheeler CM, et al (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med, 356, 1928-43.
  19. Garland SM, Brotherton JM, Skinner SR, et al (2008a). Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention. Vaccine, 26, 80-8.
  20. Garland SM, Cuzick J, Domingo EJ, et al (2008b). Recommendations for cervical cancer prevention in Asia Pacific. Vaccine, 26, 89-98.
  21. Garland SM (2009). Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J Med Res, 130, 311-21.
  22. Garland SM (2011). Human papillomavirus vaccination: where to now? Sex Transm Infect, 87, 23-4.
  23. Garland SM, Bhatla N, Ngan HY (2012). Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev, 21, 1414-22.
  24. GAVI. Human Papilloma Virus vaccine support [Online]. Available: [Accessed 17th of January 2015].
  25. Gertig DM, Brotherton JM, Budd AC, et al (2013). Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med, 11, 227.
  26. Goldie SJ, Diaz M, Kim SY, et al (2008). Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine, 26, 17-29.
  27. Hernandez BY, Ka'opua LS, Scanlan L, et al (2013). Cervical and anal human papillomavirus infection in adult women in American Samoa. Asia Pac J Public Health, 25, 19-31.
  28. IARC (2012). GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012 [Online]. Available: [Accessed 31st August 2014].
  29. Joura EA, Ault KA, Bosch FX, et al (2014). Attribution of 12 high-risk human papilloma virus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev, 23, 1997-2008.
  30. Law I, Fong JJ, Buadromo EM, et al (2013). The high burden of cervical cancer in Fiji, 2004-07. Sex Health, 10, 171-8.
  31. Levin CE, Van Minh H, Odaga J, et al (2013). Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bulletin World Health Organization, 91, 585-92.
  32. McAdam M, Sakita J, Tarivonda L, Pang J, Frazer IH (2010). Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PLoS One, 5, 13266.
  33. Mishra SI, Luce-Aoelua PH, Hubbell FA (2001). Predictors of papanicolaou smear use among American Samoan women. J Gen Intern Med, 16, 320-4.
  34. Ngan HY, Garland SM, Bhatla et al (2011). Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control. J Cancer Epidemiol, 2011, 794861.
  35. Obel J, Souares Y, Hoy D, et al (2014). A systematic review of cervical cancer incidence and mortality in the Pacific region. Asian Pac J Cancer Prev, 15, 9433-7
  36. Parkin DM, Louie KS, Clifford G (2008). Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine, 26, 1-16.
  37. Secretariat of the Pacific Community (2011). Tahiti Nui Declaration [Online]. Available: [Accessed 7th of January 2015].
  38. Secretariat of the Pacific Community (2013). Statistics for Development Division, Pacific islands Population [Online]. Available: [Accessed 25th December 2014].
  39. Tabone T, Garland SM, Mola G, et al (2012). Prevalence of human papillomavirus genotypes in women with cervical cancer in Papua New Guinea. Int J Gynaecol Obstet, 117, 30-2.
  40. Tabrizi SN, Law I, Buadromo E, et al (2011). Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji. Sex Health, 8, 338-42.
  41. Townsend JS, Stormo AR, Roland KB, et al (2014). Current cervical cancer screening knowledge, awareness, and practices among US Affiliated Pacific Island providers:opportunities and challenges. Oncology, 19, 383-93.
  42. Tsu VD, Jeronimo J, Anderson BO (2013). Why the time is right to tackle breast and cervical cancer in low-resource settings. Bull WHO, 91, 683-90.
  43. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  44. WHO (2009). Human papillomavirus vaccines: WHO position paper. Biologicals, 37, 338-44.
  45. WHO (2013). WHO vaccine-preventable disease monitoring system [Online]. Available: [Accessed 3rd of December 2013].
  46. WHO (2014a). Comprehensive cervical cancer control: A guide to essential practice. 2nd Edition ed., Geneva, Switzerland [Online]. Available: [Accessed 25rd of December 2014].
  47. WHO (2014b). Weekly epidemiological record. World Health Organization [Online]. Available: [Accessed 3rd of January 2015].

Cited by

  1. Cervical Cancer Screening in the United States–Affiliated Pacific Islands vol.20, pp.1, 2016,
  2. Post-hegemonic regionalism in Oceania: examining the development potential of the new framework for Pacific regionalism vol.31, pp.1, 2018,